Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

v3.21.2
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2021
Net Loss Per Share  
Schedule of reconciliation of net loss

For the Three Months Ended

For the Nine Months Ended

September 30, 

September 30, 

    

2021

    

2020

    

2021

    

2020

Net loss

$

(7,548,225)

$

(8,916,433)

$

(21,791,941)

$

(19,826,671)

Net loss - Non-controlling interest

 

(115,505)

 

(64,824)

 

(283,846)

 

(228,526)

Net loss attributable to Heat Biologics, Inc.

$

(7,432,720)

$

(8,851,609)

$

(21,508,095)

$

(19,598,145)

Weighted-average common shares outstanding, basic and diluted

 

25,137,628

 

20,532,696

 

24,828,438

 

13,783,039

Net loss per share, basic and diluted

$

(0.30)

$

(0.43)

$

(0.87)

$

(1.42)

Schedule of potentially dilutive securities

    

2021

    

2020

Outstanding stock options

 

1,890,174

 

1,308,124

Restricted stock subject to forfeiture and restricted stock units

 

259,874

 

289,316

Outstanding common stock warrants

 

747,383

 

819,866